Isolators
pure²
SKAN’s pure² isolator for laboratory and hospital processes
- Standard
- CFR 21 Part 11
- Standard
- DIN 12980
As the first quality control analytics company specialized in Advanced Therapy Medicinal Products (ATMPs), QVance is redefining quality control for the next generation of therapies.
In this case study, Lindsay Davies CEO from QVance, shares insights into the unique challenges of Cell & Gene therapy workflows — where batches are small, therapies are highly valuable, and every sample matters. The goal is clear: reduce the amount of product required for quality control testing so that more therapies reach patients while helping lower overall treatment costs.
To achieve this, QVance was looking for more than just a supplier. They needed a long-term partner with expertise in Cell & Gene applications and strong support throughout installation and operation.
Together, QVance and SKAN are supporting the future of Cell & Gene therapies — a future that holds tremendous potential for the treatment of rare and life-changing diseases.